Startup profile for Xlue: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

Xlue funding, valuation and investors

Research-stage AI predicting future disease risk from patient medical histories.

Verified company research · funding, investors and latest developments

Keep track of Xlue

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Seed (disclosed; legal close date unverified)

$35M · November 18, 2026

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$35M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

seed · United States (Carnegie Mellon origins; current legal headquarters unverified)

Investors in latest funding

Lead: Conviction

Sources: latest funding · tollbit.forbes.com Last verified: 2026-11-21

Overview

Xlue researches health-state/action AI models for predicting future disease risk from electronic health records and exploring possible trial simulations. Its medical use and pricing are not verified as generally available.

Why Xlue is interesting

CMU spinout disclosed $35M Seed led by Conviction on Nov 18 2026. Promising HealthSAW retrospective data, but no proven prospective clinical outcomes.

Product & use cases

HealthSAW is a research-stage model intended to forecast future diagnoses from records and clinical events, not a verified commercial cancer diagnostic or validated causal-treatment simulator. No published pricing.

  • Hospitals: retrospective/prospective studies of disease-risk screening and clinician triage
  • Drug developers: exploratory models of trial design and treatment trajectories; actual efficacy unproven

Key facts

  • CEO Chenyan Xiong; CMU spinout cofounders include Hao-Ren Yao and Ophir Frieder.
  • 2025 CATCH-FM 30k cohort, Forbes-reported later 80k cohort and Protege HealthSAW 2.5k test are distinct studies.
  • Research partner hospitals and pharma prospects; no proven widespread clinical rollout or published commercial pricing.

Funding history (newest first)

Seed (disclosed; legal close date unverified)

2026-11-18 $35M

Source: Read source · tollbit.forbes.com

Investors in our directory

Funds linked from Xlue's profile — open a fund page for stage focus and related deal articles.

Competitive landscape

In Protege's Oct 2026 2,500-patient, 16-task quasi-double-blind test, HealthSAW reported mean 37% sensitivity at 95% specificity compared with 30% XGBoost and 26.5% frontier model. Task-specific fine-tuning differs. This is not prospective efficacy; clinical false positives and workflow need validation.

  • TRACER EHR prediction model adjacent

    Academic prediction research with health system external validation.

  • Epic clinical decision-support ecosystem incumbent

    Native EHR distribution and clinical workflows; no verified direct comparison.

  • Tempus AI adjacent

    Oncology data, diagnostics and analytics: different commercial product set.

  • Knit Health adjacent

    Healthcare-model research on clinical actions; distinct benchmarks.

Market / IPO context

Editorial / static context — not a live quote.

FAQs about Xlue

Practical answers founders, operators, and investors typically search for.

The evidence establishes retrospective risk-stratification research, not an approved diagnostic or proven patient outcome.
Neither the funding valuation nor commercial pricing was disclosed in the reviewed sources.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.